Crown (CCK) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
5 Feb, 2026Executive summary
Achieved record adjusted EBITDA of $2.1 billion in 2025, up 8% year-over-year, and record free cash flow of $1,146 million, a $332 million increase year-over-year.
Adjusted EPS for Q4 was $1.74, up 9% year-over-year; full-year adjusted EPS rose 22% to $7.79.
Net leverage ratio reduced to 2.5x, the lowest in over 15 years, down from 2.7x at 2024 year-end.
Returned $625 million to shareholders in 2025 via dividends and share repurchases.
Reported EPS was $1.31 in Q4, down from $3.02 due to a prior-year gain from the Eviosys sale.
Financial highlights
Full year net sales increased to $12,365 million from $11,801 million, driven by higher shipments and material cost pass-throughs.
Q4 net sales rose 8% year-over-year, driven by 3% global beverage can volume growth, higher raw material costs, and favorable FX.
Net income attributable to shareholders was $738 million, up from $424 million in 2024.
Operating cash flow reached $1,530 million, with adjusted free cash flow at $1,146 million.
Segment income for Q4 was $420 million, slightly down from $428 million in the prior year.
Outlook and guidance
2026 adjusted diluted EPS expected between $7.90 and $8.30; Q1 2026 adjusted EPS projected at $1.70–$1.80.
2026 free cash flow estimated at $900 million after $550 million in capital spending for growth projects in Brazil, Greece, and Spain.
Net leverage expected to remain at 2.5x; guidance includes $350–$360 million net interest expense, 25% tax rate, and $330 million depreciation.
Latest events from Crown
- Board recommends director elections, auditor ratification, pay approval, and opposes written consent.CCK
Proxy filing23 Mar 2026 - Strong global beverage can growth, higher earnings, and a $2B buyback program announced.CCK
Q2 20243 Feb 2026 - Strong beverage can growth and higher income offset by pension settlement charges.CCK
Q3 202419 Jan 2026 - Record EBITDA, strong cash flow, and reduced leverage highlight a positive 2025 outlook.CCK
Q4 20248 Jan 2026 - Q1 net income up to $193M, adjusted EPS up 64%, and guidance raised on strong can demand.CCK
Q1 20256 Jan 2026 - Board backs director elections, auditor, and pay, but opposes political spending disclosure proposal.CCK
Proxy Filing1 Dec 2025 - Q2 adjusted EPS up 19%, sales and cash flow strong, and guidance raised for the year.CCK
Q2 20254 Nov 2025 - Q3 2025 delivered higher sales, strong European growth, and raised guidance with robust shareholder returns.CCK
Q3 202530 Oct 2025